Clinical Trial: Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional




Official Title: Subcutaneous Cladribine Plus Pegylated Interpheron Alfa-2a in Advanced Systemic Mastocytosis With D816V and Other Exon 17 KIT Mutations.

Brief Summary: The aim of this study is to evaluate the efficacy in terms of clinical and biological response rates of Cladribine plus Pegylated Interpheron alpha-2a therapy in patients with advanced systemic mastocytosis carrying D816V or other exon 17 KIT mutations.